sertraline + bupropion + desvenlafaxine

This is a combination of three antidepressant medications—sertraline, bupropion, and desvenlafaxine. Each drug has a distinct mechanism of action targeting different neurotransmitter systems in the brain: - **Sertraline** is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels by inhibiting its reuptake into presynaptic neurons. - **Bupropion** is an atypical antidepressant that primarily inhibits the reuptake of norepinephrine and dopamine, with minimal direct effect on serotonin. - **Desvenlafaxine** is a serotonin-norepinephrine reuptake inhibitor (SNRI), increasing both serotonin and norepinephrine concentrations. The rationale for combining these agents is to achieve broader modulation of monoaminergic neurotransmission—serotonin, norepinephrine, and dopamine—which may be beneficial in treatment-resistant depression or when monotherapy fails. This combination targets multiple pathways implicated in mood regulation. However, this triple combination does not have regulatory approval as a fixed-dose product; it would be prescribed off-label as individual agents taken together under close medical supervision due to increased risk for adverse effects such as seizures or serotonergic toxicity[1][3][9].